Drugs / LFn-p24
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00412477 | Aug 2004 → Mar 2006 | HIV infectious disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lfn-p24 | “HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn.” NCT00412477 ↗ |
| Known as | HIV LFn-p24 | “HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn.” NCT00412477 ↗ |
| Route | Intramuscular | “Product is administered IM, 1ml.” NCT00412477 ↗ |